After Hours Summary: AMBA +5.5%, MDLA +4.4%, APPS +2.6%, ZM +2.5% higher on earnings; HPE -1.2% lower on earnings; SLCT +19.8% jumps as it gets acquiredAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: AMBA +5.5%, MDLA +4.4%, APPS +2.6%, ZM +2.5%, SMG +1.5% (raises FY21 EPS and revenue guidance)
Companies trading higher in after hours in reaction to news: SLCT +19.8% (FBNC to acquire SLCT in all-stock transaction), OSTK +3.9% (looking to possibly sell tZERO unit or seek partners, according to CoinDesk), ALSN +1.6% (launches Allison FracTran, its next-gen hydraulic fracturing transmission), KODK +0.9% (issues statement in response to New York Attorney General), STIC +0.8% (closes combination with Barkbox; to trade under ticker "BARK" beginning June 2), TMO +0.4% (MRNA enters into manufacturing agreement with TMO for COVID-19 vaccine), AVTR +0.1% (acquires RIM Bio), ADCT +0.1% (stock offering)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: STNE -1.8%, HPE -1.2%, FLT -0.1% (provides guidance following the close of the AFEX acquisition)
Companies trading lower in after hours in reaction to news: IRTC -12.9% (CEO departs), GSMG -8.5% (stock offering), BYRN -8.1% (stock offering), WPRT -4.6% (files for $100 mln common stock offering), CMBM -4.1% (files for 2 mln share offering by selling shareholders), PUMP -3.4% (files for mixed shelf offering), HHR -3.2% (commences 4.5 mln ADS offering by selling shareholders), ASMB -1.2% (CFO to resign), AQB -0.7% (reports first harvest of genetically engineered Atlantic salmon), SYF -0.6% (announes organizational changes), MRNA -0.6% (MRNA enters into manufacturing agreement with TMO for COVID-19 vaccine), NVTA -0.6% (stock offering), TSLA -0.3% (SEC told Tesla last year that Elon Musk's tweets violated court-ordered policy, according to WSJ), MSM -0.1% (acquires majority interest in Wm. F. Hurst Co), EW -0.1% (Acumen Hypotension Prediction Index software receives FDA clearance), NVS -0.1% (receives FDA approval for Cosentyx as treatment for children and adolescents with psoriasis)